REVAXIS

This brand name is authorized in Austria, France, Ireland, Malta, Netherlands, UK.

Active ingredients

The drug REVAXIS contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII 3U7E3O07S8 - CORYNEBACTERIUM DIPHTHERIAE
 
Read more about Diphtheria toxoid
2
UNII K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)
 
Read more about Tetanus toxoid
3
UNII 0LVY784C09 - POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)
 
Read more about Poliomyelitis, serotype 1
4
UNII 23JE9KDF4R - POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED)
 
Read more about Poliomyelitis, serotype 2
5
UNII 459ROM8M9M - POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)
 
Read more about Poliomyelitis, serotype 3

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
J07CA01 Diphtheria-poliomyelitis-tetanus J Antiinfectives for systemic use → J07 Vaccines → J07C Bacterial and viral vaccines, combined → J07CA Bacterial and viral vaccines, combined
Discover more medicines within J07CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
FR Base de données publique des médicaments 60917345
GB Medicines & Healthcare Products Regulatory Agency 73745
MT Medicines Authority AA1438/05501, AA1438/05502, AA565/37901, AA573/01901
NL Z-Index G-Standaard 14818434
NL Z-Index G-Standaard, PRK 67830

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈